Active Biotech AB Interim Report January - September 2013
(Thomson Reuters ONE) -
Laquinimod
* Analysis of data from the Phase III ALLEGRO study shows that laquinimod
provides a beneficial impact on brain tissue damage; Laquinimod-treated
patients accumulated significantly less brain tissue damage caused by
neurodegeneration
* New data presented at ECTRIMS shows that laquinimod has an effect on both
inflammation and the underlying mechanisms associated with disease
progression in multiple sclerosis
* Teva is planning to commence clinical trials in Huntington's disease and
primary progressive multiple sclerosis (PPMS)
* Teva will initiate a further clinical trial in multiple sclerosis
(LIBRETTO)
Tasquinimod
* Phase III 10TASQ10 study is proceeding as planned; the primary analysis of
progression-free survival (PFS) and survival (OS) is expected in 2014
* Active Biotech received a milestone payment of EUR 12 M from
Ipsen
ANYARA
* Detailed analysis provides further support for ANYARA's efficacy in a
biomarker-defined sub-group of renal cell cancer patients; the result from
the Phase II/III study was presented at the 2013 European Cancer Congress
Paquinimod (57-57)
* Evaluation under way of clinical trial in systemic sclerosis
ISI
* Project proceeding according to plan
Financial summary
SEK M Q3 Jan
Jan - Sept - Dec
2013 2012 2013 2012 2012
-------------------------------------------------------------------------------
Net sales 107.0 39.8 111.9 136.4 227.9
Operating loss 27.9 -48.2 -128.6 -168.7 -163.2
Profit/Loss 29.2 -51.6 -130.0 -175.1 -175.0
after tax
Profit/loss per 0.39 -0.75 -1.77 -2.54 -2.54
share
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95
Hans Kolam, CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB(Corp. Reg. No. 556223-9227)
Box 724, 220 07 Lund
Tel: +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00
The report is also available at www.activebiotech.com
Active Biotech AB Interim Report January ? September 2013 :
http://hugin.info/1002/R/1741192/584931.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1741192]
Unternehmensinformation / Kurzprofil:
Datum: 07.11.2013 - 08:30 Uhr
Sprache: Deutsch
News-ID 313793
Anzahl Zeichen: 3384
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 100 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim Report January - September 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
